Mirae Asset Global Investments Co. Ltd. Cuts Stock Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Mirae Asset Global Investments Co. Ltd. lowered its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 22.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 112,677 shares of the company’s stock after selling 32,293 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in GoodRx were worth $755,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Citigroup Inc. grew its position in GoodRx by 301.7% during the 3rd quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock worth $45,000 after purchasing an additional 6,006 shares during the last quarter. Mackenzie Financial Corp purchased a new stake in GoodRx during the 3rd quarter worth approximately $68,000. Harbor Capital Advisors Inc. grew its position in GoodRx by 22.7% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 14,995 shares of the company’s stock worth $84,000 after purchasing an additional 2,771 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in GoodRx during the 4th quarter worth approximately $115,000. Finally, Barclays PLC grew its position in GoodRx by 219.8% during the 2nd quarter. Barclays PLC now owns 18,509 shares of the company’s stock worth $102,000 after purchasing an additional 12,722 shares during the last quarter. Hedge funds and other institutional investors own 63.77% of the company’s stock.

Analyst Ratings Changes

GDRX has been the topic of several research analyst reports. KeyCorp raised shares of GoodRx from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research report on Wednesday, April 10th. Leerink Partnrs reaffirmed an “outperform” rating on shares of GoodRx in a report on Monday, February 26th. Wells Fargo & Company raised shares of GoodRx from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $7.50 to $10.00 in a report on Monday, March 25th. TD Cowen upped their price objective on shares of GoodRx from $12.00 to $14.00 and gave the company an “outperform” rating in a report on Friday, March 1st. Finally, Truist Financial upped their price objective on shares of GoodRx from $7.50 to $8.00 and gave the company a “hold” rating in a report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, GoodRx currently has a consensus rating of “Hold” and an average price target of $8.78.

GoodRx Trading Down 0.1 %

Shares of GDRX opened at $6.96 on Thursday. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.85. GoodRx Holdings, Inc. has a 12-month low of $4.14 and a 12-month high of $9.37. The firm has a 50-day moving average price of $6.91 and a 200 day moving average price of $6.25. The firm has a market capitalization of $2.75 billion, a P/E ratio of -347.83, a P/E/G ratio of 3.65 and a beta of 1.42.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Thursday, February 29th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.02. The firm had revenue of $196.64 million during the quarter, compared to analyst estimates of $195.59 million. GoodRx had a negative net margin of 1.18% and a positive return on equity of 2.45%. Sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.23 EPS for the current year.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.